MedTrace Logo

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

NCT00073216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2021-10-14

No results posted yet for this study

Summary

To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable. The purpose of this study is to test the safety of and immune response to a novel combination HIV vaccine in HIV uninfected adults. This study will also test the safety of and immune response to a protein vaccine given alone.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

Clade B gag DNA/PLG and env DNA/PLG Microparticles

BIOLOGICAL

Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Paul Spearman · Vanderbilt University

  • Michelle Lally · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073216 on ClinicalTrials.gov